Skip to main content

Affimed to Report First Quarter 2020 Financial Results & Corporate Update June 23, 2020; Company to Participate in Virtual BMO Prescriptions for Success Healthcare Conference


Heidelberg, Germany, June 16, 2020 – Affimed N.V. (Nasdaq: AFMD), a clinical stage immuno-oncology company committed to giving patients back their innate ability to fight cancer, today announced that it will release first quarter 2020 results on Tuesday, June 23, 2020 and host a conference call at 8:30 a.m. EDT to discuss financial results and recent corporate developments.The conference call will be available via phone and webcast. To access the first quarter results call, please dial +1-646-741-3167 for U.S. callers, or +44 (0) 2071 928338 for international callers, and reference conference ID 8594214 approximately 15 minutes prior to the call.To access the live audio webcast of the conference call please visit the “Investors” section of company’s website at https://www.affimed.com/investors/webcasts_cp/. A replay of the call will be archived on the Affimed website for 30 days after the call.BMO Conference ParticipationAffimed also announced that its Chief Executive Officer, Dr. Adi Hoess, will participate in a fireside chat at the 2020 BMO Prescriptions for Success Healthcare Conference on Tuesday, June 23, at 1:30 p.m. EDT.A live webcast of the fireside chat will be available on the “Investors” section of the company’s website at https://www.affimed.com/investors/webcasts_cp?/. A replay of the fireside chat will be archived on the Affimed website for 30 days following the event.About Affimed N.V.Affimed (Nasdaq: AFMD) is a clinical-stage immuno-oncology company committed to giving patients back their innate ability to fight cancer. Affimed’s fit-for-purpose ROCK® platform allows innate cell engagers to be designed for specific patient populations. The company is developing single and combination therapies to treat hematologic and solid tumors. The company is currently enrolling patients into a registration-directed study of AFM13 for CD30-positive relapsed/refractory peripheral T cell lymphoma and into a Phase 1/2a dose escalation/expansion study of AFM24 for the treatment of advanced EGFR-expressing solid tumors. For more information, please visit www.affimed.com.Investor & Media Contact:Alex Fudukidis
Head of Investor Relations
E-Mail: a.fudukidis@affimed.com
Tel: (917) 436-8102

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals

Before you continue, please confirm the following:

Professional advisers only

I am a professional adviser and would like to visit the GOLDEA CAPITAL for Professionals website.

Important Notice for Investors:

The services and products offered by Goldalea Capital Ltd. are intended exclusively for professional market participants as defined by applicable laws and regulations. This typically includes institutional investors, qualified investors, and high-net-worth individuals who have sufficient knowledge, experience, resources, and independence to assess the risks of trading on their own.

No Investment Advice:

The information, analyses, and market data provided are for general information purposes only and do not constitute individual investment advice. They should not be construed as a basis for investment decisions and do not take into account the specific investment objectives, financial situation, or individual needs of any recipient.

High Risks:

Trading in financial instruments is associated with significant risks and may result in the complete loss of the invested capital. Goldalea Capital Ltd. accepts no liability for losses incurred as a result of the use of the information provided or the execution of transactions.

Sole Responsibility:

The decision to invest or not to invest is solely the responsibility of the investor. Investors should obtain comprehensive information about the risks involved before making any investment decision and, if necessary, seek independent advice.

No Guarantees:

Goldalea Capital Ltd. makes no warranties or representations as to the accuracy, completeness, or timeliness of the information provided. Markets are subject to constant change, and past performance is not a reliable indicator of future results.

Regional Restrictions:

The services offered by Goldalea Capital Ltd. may not be available to all persons or in all countries. It is the responsibility of the investor to ensure that they are authorized to use the services offered.

Please note: This disclaimer is for general information purposes only and does not replace individual legal or tax advice.